What is Semaglutide Peptide?

By 
Dr Amit Kumar Singh
 on 
Nov 20, 2025
 • 
5
 min read

Have you been searching for an effective solution to manage blood sugar levels or support weight loss? For many, managing diabetes or losing weight can feel like a constant struggle, with diets and treatments often failing to deliver lasting results. But what if there was a medication that could effectively help manage both blood glucose levels and weight? Enter semaglutide, a peptide classified as a GLP-1 (glucagon-like peptide-1) receptor agonist that has rapidly gained recognition for its potential to address both of these challenges.

Semaglutide works by mimicking the actions of GLP-1, a hormone that plays a critical role in regulating appetite and blood sugar. With its unique dual benefit, semaglutide has shown the potential to help individuals lose up to 15% of their body weight within a year— a significant and promising outcome for those who have struggled to achieve their weight loss or blood glucose targets. Studies show that medications like semaglutide not only help lower hba1c levels in diabetes patients but also support a gradual, healthy weight loss journey, offering new hope for individuals who have faced frustration with traditional methods.

How Does Semaglutide Work?

Semaglutide, marketed under the brand names Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained significant attention for its effectiveness in managing weight and controlling blood sugar levels in individuals with type 2 diabetes. By mimicking the natural hormone GLP-1, semaglutide plays a crucial role in appetite regulation, satiety, and glucose metabolism. It functions by mimicking the action of GLP-1, a hormone produced in the intestines that is released in response to food intake. When GLP-1 is secreted, it stimulates insulin secretion from pancreatic beta cells while inhibiting glucagon release from alpha cells. This dual action helps lower blood glucose levels and improves glycemic control.

Impact on Appetite and Satiety

1. Appetite regulation: Clinical studies demonstrate that semaglutide significantly reduces appetite. For instance, a randomised controlled trial published in Diabetes Care found that participants using semaglutide experienced a 24% reduction in total energy intake compared to those on placebo. This reduction was attributed to decreased hunger and food cravings, as well as better control over eating behaviours.

2. Satiety Enhancement: Semaglutide enhances feelings of fullness after meals. In a study assessing the effects of oral semaglutide on energy intake, participants reported improved satiety scores after consuming meals, particularly after high-calorie breakfasts. The results indicated that total daily energy intake was reduced by approximately 38.9% with semaglutide compared to placebo, showcasing its effectiveness in promoting satiety.

3. Slowing Gastric Emptying: Semaglutide also slows gastric emptying, which prolongs the time food remains in the stomach. This mechanism contributes to prolonged feelings of fullness and helps prevent rapid spikes in blood sugar levels after meals.

Blood Sugar Regulation

Semaglutide's impact extends beyond appetite control; it plays a vital role in blood sugar regulation:

  1. Insulin Secretion: By enhancing glucose-dependent insulin secretion, semaglutide helps maintain lower blood glucose levels during fasting and postprandial states. A clinical trial demonstrated that participants experienced an average weight loss of 5.0 kg alongside improved glycemic control after 12 weeks of treatment with semaglutide.
  2. Reduction of Glucagon Levels: Semaglutide reduces glucagon secretion, which decreases hepatic glucose production. This action is particularly beneficial for individuals with type 2 diabetes who often experience elevated glucagon levels

Semaglutide for Weight Loss

Clinical trials have demonstrated its potential to lead to substantial and sustained weight reductions, making it a valuable option for those struggling with weight management.

Clinical Trials Proving the Efficacy of Semaglutide

  1. STEP 1 Trial: The STEP 1 trial was pivotal in establishing the efficacy of semaglutide for weight loss. Conducted over 68 weeks, this double-blind study involved 1,961 adults with a body mass index (BMI) of 30 or greater (or ≥27 with weight-related conditions) who were assigned to receive either semaglutide (2.4 mg) or a placebo alongside lifestyle interventions. Results showed that participants receiving semaglutide experienced an average weight loss of 14.9% from baseline, compared to just 2.4% in the placebo group, representing a treatment difference of 12.4 percentage points (P<0.001).
  2. SELECT Trial: The SELECT trial further evaluated semaglutide's long-term effects on weight loss in individuals without diabetes but with pre-existing cardiovascular conditions. Over a period of 208 weeks, participants treated with semaglutide experienced a mean weight reduction of 10.2%, compared to just 1.5% in the placebo group (P<0.0001). This study demonstrated that the benefits of semaglutide extend beyond short-term results, showing sustained efficacy over time.
  3. Real-World Evidence: A cohort study involving 175 patients treated with semaglutide in a clinical setting reported similar outcomes to those seen in randomised trials, with an average weight loss of 5.9% at 3 months and 10.9% at 6 months. This suggests that semaglutide can be effective outside the controlled environments of clinical trials.

Factors Influencing Weight Loss

Several factors can influence the effectiveness of semaglutide in promoting weight loss:

  1. Dosage: The standard dose for weight management is typically set at 2.4 mg once weekly, which has been shown to produce significant weight loss results. Higher doses may lead to increased efficacy; however, they may also heighten the risk of side effects.
  2. Adherence: Adherence to the prescribed regimen is critical for achieving optimal results with semaglutide. In the STEP trials, adherence rates were high, with around 81% of participants completing the treatment protocol. Discontinuation due to side effects such as nausea and diarrhoea was noted, but many participants reported these effects as transient and manageable.

Safety and Side Effects of Semaglutide

Semaglutide therapy usually presents with certain gastrointestinal side effects, especially during the initial weeks. While these side effects can be concerning, it is important to reassure patients that they are generally mild and transient. Most individuals find that starting at a lower dose and gradually increasing it can help mitigate gastrointestinal symptoms. In fact, only about 2.9% of participants discontinued treatment due to adverse effects in clinical trials.

Common Side Effects

The most frequently reported side effects associated with semaglutide include:

  1. Nausea: Nausea is the most common side effect experienced by patients taking semaglutide. In clinical trials, approximately 36.6% of participants reported nausea, particularly during the initial weeks of treatment. For example, in the STEP 1 trial, about 44% of participants receiving semaglutide experienced nausea compared to just 10% in the placebo group. Most cases are mild to moderate and typically resolve as the body adjusts to the medication.
  2. Vomiting: Alongside nausea, vomiting is another common gastrointestinal side effect, affecting about 10-15% of users. This side effect is often transient and occurs more frequently during the early stages of treatment.
  3. Diarrhoea: Diarrhoea is reported by approximately 8.6% of patients in clinical studies. In the STEP 5 trial, gastrointestinal adverse events were noted in 82.2% of participants taking semaglutide compared to 53.9% in the placebo group, with diarrhoea being one of the most frequently cited issues.
  4. Constipation: Although less common than diarrhoea, constipation affects about 5-10% of users and can vary based on individual dietary habits.

Long-Term Safety

Concerns regarding the long-term safety of semaglutide have been addressed in several studies:

  1. Overall Safety Profile: Long-term studies indicate that semaglutide is considered safe for extended use. A review highlighted that while there is a slight increase in the risk of gallbladder disease (cholelithiasis), this risk remains low (approximately 1.4% for semaglutide users compared to 1.9% for placebo). Other serious risks associated with long-term use have not been substantiated by current data.
  2. Monitoring Ongoing Research: Ongoing research continues to monitor potential long-term side effects. For instance, while there have been concerns regarding pancreatitis and pancreatic cancer, studies such as those from the SUSTAIN trials have not shown a definitive link between GLP-1 receptor agonists like semaglutide and these conditions.
  3. Benefits vs Risks: The benefits of semaglutide—such as improved blood sugar control and significant weight loss—often outweigh potential risks associated with its long-term use. Research indicates that maintaining treatment can lead to sustained weight loss and lower blood pressure, which are critical for reducing the risk of cardiovascular diseases.

Specific Considerations for Women

  1. Pregnancy: Semaglutide is not recommended during pregnancy due to potential risks to the foetus. Animal studies have shown that semaglutide can cause thyroid tumours, and while human data are limited, the FDA advises discontinuing semaglutide at least two months prior to attempting conception. This recommendation is based on the need to ensure that any potential risks associated with the medication do not affect foetal development. The American College of Obstetricians and Gynecologists (ACOG) guidelines also emphasise that weight loss medications are not appropriate during conception or pregnancy due to the potential harm they may pose to both the mother and the unborn child.

  1. Breastfeeding: The safety of semaglutide during breastfeeding has been a topic of research. A study published in Nutrients examined eight nursing mothers using subcutaneous semaglutide and found no detectable levels of the drug in their breast milk. This suggests a minimal risk of exposure for breastfed infants. However, it is important to monitor maternal nutrition closely, as semaglutide's appetite-suppressing effects could inadvertently impact milk supply and nutritional intake necessary for both mother and child. The study highlighted that while semaglutide was not found in significant amounts in breast milk, ongoing monitoring for any gastrointestinal discomfort in infants is recommended.

  1. Hormonal Factors: Women may experience unique hormonal fluctuations throughout their life stages—such as during menstruation, pregnancy, and menopause—that can influence weight management and metabolic health. These hormonal changes can affect how women respond to medications like semaglutide. For instance, fluctuations in oestrogen and progesterone can impact appetite regulation and fat distribution, potentially altering the efficacy of weight loss treatments.

Consulting

Given the specific considerations surrounding semaglutide use in women, it is essential to consult with healthcare providers before starting this medication. A healthcare professional can provide personalised advice based on individual health profiles, including pre-existing conditions related to reproductive health or metabolic disorders. They can also help navigate potential risks associated with medication use during pregnancy or lactation.

Semaglutide and Lifestyle Changes

Semaglutide effectiveness is significantly enhanced when combined with healthy lifestyle modifications, including diet and exercise. This combination not only supports the medication's weight loss effects but also promotes overall health and well-being.

The Role of Lifestyle Modifications

  1. Diet: A balanced diet is crucial for maximising the benefits of semaglutide. Clinical studies have shown that dietary changes can enhance weight loss outcomes when used in conjunction with this medication. 

Key dietary recommendations: Increase Fibre Intake

  1. Exercise: Regular physical activity is a cornerstone of effective weight management and diabetes control. The NICE recommends at least 150 minutes of moderate-intensity aerobic exercise per week for individuals with type 2 diabetes.

How Semaglutide Supports Lifestyle Changes

Semaglutide aids individuals in making healthier choices by enhancing feelings of fullness and reducing appetite. This pharmacological support allows users to better adhere to dietary recommendations and engage more consistently in physical activity:

  1. Appetite Suppression: By mimicking the action of GLP-1, semaglutide helps users feel satisfied with smaller portions, making it easier to stick to a balanced diet.
  2. Improved Energy Levels: Many users report increased energy levels when on semaglutide, which can motivate them to engage in regular physical activity.

Conclusion

Semaglutide is a highly effective GLP-1 receptor agonist that plays a significant role in weight management and the treatment of type 2 diabetes. Clinical trials have consistently demonstrated its efficacy. However, it is essential to recognize that semaglutide is not a standalone solution. The integration of healthy lifestyle changes—including a balanced diet and regular physical activity—is crucial for maximising the benefits of this medication. Additionally, women must consider specific health factors related to pregnancy and breastfeeding when evaluating the use of semaglutide.

Before starting semaglutide or any weight loss medication, consulting with a healthcare provider is vital. A healthcare professional can provide personalised guidance based on individual health profiles, helping patients make informed decisions about their treatment options.

While semaglutide offers promising results for weight loss and metabolic health, the best outcomes are achieved through a comprehensive approach that includes medical intervention and lifestyle modifications. By working closely with healthcare providers, individuals can develop effective strategies tailored to their unique needs and goals.

Frequently Asked Questions

1. What exactly is semaglutide?
Semaglutide is a peptide medication classified as a GLP-1 receptor agonist. It works by mimicking a natural hormone in the body that helps regulate blood sugar and appetite, making it beneficial for diabetes management and weight loss.

2. How does semaglutide assist with weight loss?
Semaglutide activates GLP-1 receptors that play a role in appetite control and digestion. By reducing hunger and increasing feelings of fullness, it supports sustainable weight loss over time.

3. Is semaglutide only for those with diabetes?
No, semaglutide is also approved for use as a weight loss medication, even for people without diabetes. The brand name Wegovy is commonly prescribed specifically for weight management in non-diabetic individuals.

4. How soon can I expect to see results with semaglutide?
Results can vary, but some individuals notice changes in appetite and weight within the first few weeks. Full benefits, however, often take several months with consistent use.

5. What are the possible side effects of semaglutide?
Common side effects include nausea, vomiting, and digestive discomfort, especially at the start. These effects are generally manageable, and your healthcare provider can offer tips to minimize them.

References

  1. Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2021). Effects of semaglutide on appetite control, ad libitum energy intake, and food preference in subjects with obesity. Diabetes, Obesity and Metabolism, 23(2), 135–144. https://doi.org/10.1111/dom.14209
  2. Guo, J., Chen, Y., Zhang, X., & Liu, A. (2022). Mechanisms of action of glucagon-like peptide-1 receptor agonists in body weight regulation and potential application in obesity treatment. Frontiers in Endocrinology, 13, 9486455. https://doi.org/10.3389/fendo.2022.9486455
  3. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2023). Effects of tirzepatide versus semaglutide on weight reduction in individuals with obesity: A randomised controlled trial. The New England Journal of Medicine, 389(6), 503-515. https://doi.org/10.1056/NEJMoa230756
  4. Iepsen, E. W., Lundgren, J., Holst, J. J., Madsbad, S., & Torekov, S. S. (2021). Semaglutide-induced weight loss in patients with obesity. Diabetes, Obesity and Metabolism, 23(2), 155-161. https://doi.org/10.1111/dom.14232
  5. National Institute for Health and Care Excellence. (n.d.). Physical activity. NICE. https://www.nice.org.uk/guidance/qs84
  6. Lundgren, J. R., Janus, C., Jensen, S. B., Pedersen, O., Juhl, C. R., Christensen, R., Holst, J. J., & Torekov, S. S. (2021). The efficacy of semaglutide in patients with obesity: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 23(3), 747-755. https://doi.org/10.1111/dom.14218
  7. Ross, K., Dennis, S., & Macdonald, J. (2022). Healthcare professionals’ perspective on delivering personalised and holistic care: Using the theoretical domains framework. BMC Health Services Research, 22, 1278. https://doi.org/10.1186/s12913-022-08934-7
Take charge of how you look and feel.
Backed by science. Guided by experts.

SheMed’s medical weight loss programme combines expert care and science-backed treatment to help you feel and look your best — for life.
The content on the SheMed blog is provided for general informational and educational purposes only. While SheMed provides professional weight loss services and strives to ensure the information shared is accurate and up to date, we make no representations or guarantees as to its accuracy, completeness, or timeliness. This content should not be taken as personal medical advice or a substitute for consultation with a qualified healthcare provider. Always speak with your doctor or licensed medical professional about your individual health or medical needs before starting any new treatment or programme. Never disregard or delay seeking professional medical advice because of something you have read on this site.  SheMed is not responsible for any actions you may take based on the information provided in this blog.

Subscribe to our Newsletter

To receive an email when we go live and other information about our products and services, please leave your email above. To see how we use your email, please click here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.